Testing a tailored immunotherapy approach for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at using a blood test (ctDNA) to guide whether patients with advanced or recurrent cervical cancer can safely reduce their immunotherapy treatment. It aims to maintain effectiveness while lowering side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread (stage IVB) or come back after initial treatment, and you have not had systemic treatment (like chemotherapy) for this new or advanced stage.
- You are between 18 and 75 years old and are female.
- You have at least one tumor that can be measured on imaging scans (like CT or MRI).
- You are generally active and able to care for yourself (ECOG performance status 0-1).
- Your organ functions (blood counts, kidney, liver) must be within acceptable levels as per the trial's guidelines.
- You have not had certain previous treatments, like immunotherapy or major surgery within a specified time before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
Hear when a new Uterine Cervical Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.